# Metformin to Reduce Heart Failure After Myocardial Infarction

Study · id `cardio:ct-nct01217307` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01217307](<https://clinicaltrials.gov/study/NCT01217307>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01217307

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Heart failure; Acute care and long-term living  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 380 participants.

## Technical summary

Registry record NCT01217307. Randomized; quadruple masking; primary purpose treatment. Start 2011-01 (registry gives no type); primary completion 2013-10 (actual). Results posted on 2018-01-30.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 380 participants (enrolled count; ClinicalTrials.gov record NCT01217307, source copy `cardio:ctgov-nct01217307-2018-01-30`, retrieved 2026-10-26)
- Start date: 2011-01 (registry gives no type) (ClinicalTrials.gov record NCT01217307, source copy `cardio:ctgov-nct01217307-2018-01-30`, retrieved 2026-10-26)
- Primary completion: 2013-10 (actual) (ClinicalTrials.gov record NCT01217307, source copy `cardio:ctgov-nct01217307-2018-01-30`, retrieved 2026-10-26)
- Completion: 2015-10 (actual) (ClinicalTrials.gov record NCT01217307, source copy `cardio:ctgov-nct01217307-2018-01-30`, retrieved 2026-10-26)
- Results first posted: 2018-01-30 (ClinicalTrials.gov record NCT01217307, source copy `cardio:ctgov-nct01217307-2018-01-30`, retrieved 2026-10-26)
- Countries: Netherlands (ClinicalTrials.gov record NCT01217307, source copy `cardio:ctgov-nct01217307-2018-01-30`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01217307-2018-01-30`, retrieved 2026-10-26)

## The registry's words

- Brief title: Metformin to Reduce Heart Failure After Myocardial Infarction
- Acronym: GIPS-III
- Condition: ST Elevation Myocardial Infarction (STEMI)
- Condition: Coronary Artery Disease
- Condition: Heart Failure
- Condition: Diabetes
- Intervention (Drug): Metformin
- Intervention (Drug): Placebo
- Lead sponsor: University Medical Center Groningen
- Lead sponsor class: OTHER
- Collaborator: ZonMw: The Netherlands Organisation for Health Research and Development
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: University Medical Center Groningen (`cardio:org-university-medical-center-groningen`)
- Registry lists this organization as a collaborator: ZonMw: The Netherlands Organisation for Health Research and Development (`cardio:org-zonmw-the-netherlands-organisation-for-health-research-and-cc2e75`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of metformin on left ventricular function after acute myocardial infarction in patients without diabetes: the GIPS-III randomized clinical trial (`cardio:pubmed-24687169`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of Metformin Treatment on Lipoprotein Subfractions in Non-Diabetic Patients with Acute Myocardial Infarction: A Glycometabolic Intervention as Adjunct to Primary Coronary Intervention in ST Elevation Myocardial Infarction (GIPS-III) Trial (`cardio:pubmed-26808474`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of Metformin on Metabolites and Relation With Myocardial Infarct Size and Left Ventricular Ejection Fraction After Myocardial Infarction (`cardio:pubmed-28100626`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Two-year follow-up of 4 months metformin treatment vs. placebo in ST-elevation myocardial infarction: data from the GIPS-III RCT (`cardio:pubmed-28755285`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Association of Circulating Ketone Bodies With Functional Outcomes After ST-Segment Elevation Myocardial Infarction (`cardio:pubmed-34593124`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: ca1b272150a6f2ac648fabd39712f61ddfab1121d5a7ca41e76033977d981fee
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
